# GLP-1 Digest: Latest Research and Clinical Updates April 25, > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-weight-loss-medicine-clinical-updates-april-25/ > **Published:** 2026-04-25T23:10:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:57:34-04:00 > **Clinical Summary:** Explore GLP-1 weight loss medicine clinical evidence including tirzepatide, semaglutide, and liraglutide for metabolic and cardiovascular benefits. --- #### Clinical Takeaway GLP-1 receptor agonists have emerged as transformative agents in metabolic medicine, with expanding evidence supporting their use beyond type 2 diabetes for [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) and cardiovascular protection. This digest examines the clinical evidence for tirzepatide, semaglutide, and liraglutide, synthesizing data on weight loss outcomes, cardiac benefits, safety profiles, and emerging applications in type 1 diabetes care. GLP-1 Digest | April 25, 2026 GLP-1 receptor agonists have emerged as transformative agents in metabolic medicine, with expanding evidence supporting their use beyond type 2 diabetes for weight management and cardiovascular protection. This digest examines the clinical evidence for tirzepatide, semaglutide, and liraglutide, synthesizing data on weight loss outcomes, cardiac benefits, safety profiles, and emerging applications in type 1 diabetes care. ### GLP-1 News - [GLP-1 Receptor Agonists in Type 1 Diabetes: Clinical Evidence](https://cedclinic.com/glp-1-receptor-agonists-in-type-1-diabetes-clinical-evidence/)GLP-1 receptor agonists show emerging clinical relevance in Type 1 diabetes management, though current evidence remains limited and requires further investigation for routine clinical application. - [Tirzepatide Weight Loss Medicine: 2026 Clinical Guide](https://cedclinic.com/tirzepatide-weight-loss-medicine-2026-guide/)Clinical Relevance Summary GLP-1 receptor agonists are evidence-based medications for weight management in adults with obesity or overweight with weight-related conditions. - [GLP-1 Receptor Agonist Clinical Evidence Guide](https://cedclinic.com/glp-1-receptor-agonist-clinical-evidence-guide/)GLP-1 Receptor Agonist Clinical Evidence Summary GLP-1 receptor agonists, including semaglutide, are evidence-based medications for managing type 2 diabetes and weight loss in adult primary care settings. - [GLP-1 Receptor Agonists: Clinical Evidence and Outcomes](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/)Summary GLP-1 receptor agonists have moderate clinical relevance for prescribers managing weight loss and obesity in adults, with evidence supporting their use in primary care settings. - [GLP-1 Receptor Agonist Side Effects and Safety](https://cedclinic.com/glp-1-receptor-agonist-adverse-events-reporting/)GLP-1 receptor agonists have moderate clinical relevance for prescribers, requiring careful interpretation of [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) and safety data when treating type 2 diabetes patients. - [GLP-1 Receptor Agonist Benefits in Cardiac Interventions](https://cedclinic.com/tirzepatide-perioperative-cardioprotective-effects-cardiac-care/)GLP-1 receptor agonists show moderate clinical relevance for patients undergoing cardiac interventions, requiring careful interpretation by prescribers. - [GLP-1 Cardiovascular Outcomes: Clinical Evidence & Safety](https://cedclinic.com/tirzepatide-cardiovascular-mortality-benefit-clinical-evidence/)GLP-1 receptor agonists demonstrate cardiovascular benefits in [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), making them relevant for prescribers treating patients with diabetes and cardiovascular disease risk factors. - [GLP-1 Receptor Agonist Clinical Evidence: Tirzepatide vs Semaglutide](https://cedclinic.com/tirzepatide-vs-semaglutide-clinical-evidence-weight-loss/)GLP-1 receptor agonists demonstrate moderate clinical relevance for obesity management, with comparative evidence between tirzepatide and semaglutide informing prescriber decision-making. - [GLP-1 Receptor Agonist Clinical Evidence: Benefits](https://cedclinic.com/glp-1-receptor-agonist-insurance-coverage-expansion/)GLP-1 receptor agonists show moderate clinical relevance for prescribers, with established benefits in weight loss and primary care management of adults with obesity. - [GLP-1 Receptor Agonist Clinical Evidence and Outcomes](https://cedclinic.com/glp-1-receptor-agonist-cancer-risk-reduction/)GLP-1 receptor agonists have moderate clinical relevance for prescribers, with evidence supporting their use in weight loss and metabolic management in adult populations. ### GLP-1 Studies - [How Cannabinoid Signaling Shapes Insulin Sensitivity in Humans](https://cedclinic.com/cannabinoid-receptor-insulin-sensitivity-study/)Clinical Relevance Summary CB1 receptor modulation may improve insulin sensitivity independently of insulin secretion, potentially offering a novel therapeutic target for metabolic disorders and diabetes management. - [GLP-1 Receptor Agonist Randomized Trial Evidence](https://cedclinic.com/glp-1-receptor-agonist-randomized-trial-data-2/)GLP-1 receptor agonists, including semaglutide and tirzepatide, show evidence of clinical benefit in randomized trials, though direct applicability requires individual clinical assessment. - [SEO Title (58 characters): GLP-1 Receptor Agonist Randomized Trial: Weight Loss Evidence](https://cedclinic.com/glp-1-receptor-agonist-weight-regain-prevention/)Clinical Relevance Summary GLP-1 receptor agonists demonstrate significant weight loss benefits in adults with obesity, supporting their use as pharmacological treatment options. - [SEO Title GLP-1 Weight Loss Cardiovascular Evidence: Clinical Trial Analysis](https://cedclinic.com/glp-1-cardiovascular-clinical-trial-evidence-analysis/)GLP-1 Weight Loss Cardiovascular Evidence: Clinical Trial Analysis GLP-1 receptor agonists demonstrate cardiovascular benefits beyond weight loss, with clinical trial data supporting their use in patients with obesity and cardiovascular disease. - [Tirzepatide Cardiovascular Safety: Clinical Trial Evidence](https://cedclinic.com/tirzepatide-cardiovascular-safety-clinical-trial-evidence/)Tirzepatide demonstrates [cardiovascular safety](https://cedclinic.com/stroke-risk-assessment-substance-use/) in clinical trials, providing evidence relevant to treatment decisions for patients with diabetes or obesity requiring cardioprotection. - [GLP-1 Receptor Agonist Randomized Trial: Clinical Evidence](https://cedclinic.com/amazon-glp-1-distribution-clinical-practice-impact/)Summary GLP-1 receptor agonists show clinical benefit for weight loss and metabolic control in adults with obesity, with applications in primary care settings. - [Semaglutide Clinical Trial Outcomes: Heart Health Data](https://cedclinic.com/semaglutide-cardiovascular-outcomes-heart-health/)Semaglutide demonstrates cardiovascular benefits in adults with type 2 diabetes through randomized controlled trial data, supporting its use in endocrinology practice. - [Semaglutide Clinical Trial Outcomes: SUSTAIN Evidence](https://cedclinic.com/semaglutide-efficacy-in-younger-adults-sustain-trial/)Summary Semaglutide demonstrated significant HbA1c reduction in type 2 diabetes patients across the SUSTAIN trial series, establishing efficacy in younger adult populations. - [GLP-1 Receptor Agonist Randomized Trial Results SEO Title (58 characters): GLP-1 Receptor Agonist Randomized Trial Heart Safety Results](https://cedclinic.com/glp-1-receptor-agonist-heart-safety-profile-trial-results/)Summary GLP-1 receptor agonists demonstrated cardiovascular safety in randomized trials, supporting their use for weight management in adults with obesity. - [SEO Title (58 characters): Semaglutide Safety in Dialysis: Clinical Trial Evidence](https://cedclinic.com/semaglutide-dialysis-safety-clinical-trial-evidence/)Clinical Relevance Summary Semaglutide safety data in dialysis patients addresses a gap in evidence for GLP-1 use in advanced kidney disease populations. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) RELATED READING AT CED CLINIC Continue exploring the evidence [GLP-1 Weight Loss: Semaglutide vs Tirzepatide Evidence](https://cedclinic.com/semaglutide-vs-tirzepatide-cardiovascular-outcomes/) Compare the clinical outcomes of semaglutide and tirzepatide for weight loss in adults with obesity and metabolic conditions. [Read Comparison](https://cedclinic.com/semaglutide-vs-tirzepatide-cardiovascular-outcomes/) [GLP-1 Receptor Agonists: Clinical Evidence and CV Outcomes](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Review cardiovascular safety and efficacy data for GLP-1 receptor agonists in diabetes and weight management. [Explore CV Data](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) [Semaglutide vs Tirzepatide: Clinical Evidence Guide](https://cedclinic.com/tirzepatide-dual-receptor-agonist-weight-loss-comparison/) Detailed guide comparing semaglutide and tirzepatide [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) for metabolic and weight loss therapies. [View Guide](https://cedclinic.com/tirzepatide-dual-receptor-agonist-weight-loss-comparison/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=GLP-1%20Digest%3A%20Latest%20Research%20and%20Clinical%20Updates%20April%2025%2C&url=https%3A%2F%2Fcedclinic.com%2Fglp-1-weight-loss-medicine-clinical-updates-april-25%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fglp-1-weight-loss-medicine-clinical-updates-april-25%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=GLP-1%20Digest%3A%20Latest%20Research%20and%20Clinical%20Updates%20April%2025%2C%20https%3A%2F%2Fcedclinic.com%2Fglp-1-weight-loss-medicine-clinical-updates-april-25%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).